LONA:NASDAQ
Athira Pharma
7,39 US$
arrow_upward
+2,07%(+0,15) 1 d
24 jul, 16:00:00 GMT-4 · USD
search
Todos los símbolos
1 d
5 d
1 m
6 m
YTD
1 a
5 a
MÁX.
| Símbolo | Precio | Cambio | % de cambio |
|---|
insights_autoGenerando estadísticas principales de LONA...
Abrir
7,52 US$
Alto
7,71 US$
Bajo
7,07 US$
Cap. merc.
69,42 M
Vol. medio
32,72 mil
Volumen
9,20 mil
Máximo en 52 sem.
14,21 US$
Mínimo en 52 sem.
4,21 US$
BPA
-20,70 US$
Beta
2,01
Acciones en circulación
9,39 M
N.º de empleados
19
Abrir
7,52 US$
Alto
7,71 US$
Bajo
7,07 US$
Cap. merc.
69,42 M
Vol. medio
32,72 mil
Volumen
9,20 mil
Máximo en 52 sem.
14,21 US$
Mínimo en 52 sem.
4,21 US$
BPA
-20,70 US$
Beta
2,01
Acciones en circulación
9,39 M
N.º de empleados
19
Noticias
De fuentes de la Web
Simply Wall Street
·
hace 4 minutos
Fulton Financial (FULT) Appoints David S. Schulz To Board And Audit Risk Committees
The Motley Fool
·
hace 16 minutos
President Trump's Strait of Hormuz Blockade Pushed the S&P 500 Down 0.79%
Crypto Briefing
·
hace 11 minutos
Semiconductors now drive nearly half of S&P 500 earnings growth, and that should make crypto investors pay attention
Investor's Business Daily
·
hace 1 hora
Dow Jones Futures: Market Triggers Sell Signal; Apple Earnings, Iran News, Fed Meeting In Focus
Perfil
Athira Pharma is a late clinical stage American biopharmaceutical company developing small-molecule therapeutics targeting neurodegenerative diseases such as Alzheimer's disease and Parkinson's disease. The company's lead candidate, ATH-1017, is in human studies for Alzheimer's disease as of 2021.
The company was founded in 2011 and is headquartered in Seattle. Funding that supports the company is from both public and private investment groups including the Alzheimer's Drug Discovery Foundation, Dolby Family Ventures, the State of Washington's Life Sciences Discovery Fund, The W Fund, WRF Capital, and other private investors.
Leen Kawas served as the company's first President and CEO, but resigned in October 2021, after an independent special committee found she "altered images in scientific papers she authored." In 2025, the company paid a $4 million settlement in relation to allegations that the CEO falsified research to secure a federal grant. On October 21, 2021, Mark Litton, Ph.D., M.B.A. became chief executive officer. Wikipedia
Acerca de Athira Pharma
El contenido generado por IA puede contener errores. Más información